Skip to main content
. Author manuscript; available in PMC: 2023 Jul 12.
Published in final edited form as: Immunity. 2022 May 27;55(7):1200–1215.e6. doi: 10.1016/j.immuni.2022.05.003

Figure 7. Antigen-specific CD4+ T cells differentiate into TCF-1+ PD-1+ cells following cell division in tumor-draining lymph nodes, but not in the tumor microenvironments.

Figure 7.

(A) Experiment design to analyze CD4+ T cell response to tumor antigen.

(B-C) Representative plots showing expression of TCF-1 and BCL6 by donor-derived OT-II CD4+ T cells harvested from tumor (TIL) and the tumor draining lymph node (tdLN). Data pooled from two experiments (n = 6 – 8 / experiment) and shown with mean±SD.

(D-F) CFSE dilution and expression of BCL6, TCF-1, CXCR6, PD-1 and CD44 by donor-derived OT-II cells. The CFSE level of naive OT-II cells was determined by recipient mice without tumor transplantation sacrificed at the same time points. Left panels in (E) show tdLN-derived OT-II cells without overlay of TIL or naive cells. Pooled data are shown with mean±SD in (F) with assessment of statistical differences by one-way ANOVA.

(G) Representative plots showing expression of CXCR6, TCF-1 and BCL6 by donor-derived OT-II CD4+ T cells harvested from tdLN and the tumor. Numbers show mean±SD.